
1. Neurobiol Aging. 2017 Nov;59:220.e1-220.e9. doi:
10.1016/j.neurobiolaging.2017.07.001. Epub 2017 Jul 14.

Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and
ABCA7 in 1779 cases and 1273 controls.

Bellenguez C(1), Charbonnier C(2), Grenier-Boley B(1), Quenez O(2), Le Guennec
K(2), Nicolas G(2), Chauhan G(3), Wallon D(4), Rousseau S(2), Richard AC(2),
Boland A(5), Bourque G(6), Munter HM(6), Olaso R(5), Meyer V(5), Rollin-Sillaire 
A(7), Pasquier F(7), Letenneur L(3), Redon R(8), Dartigues JF(3), Tzourio C(3),
Frebourg T(9), Lathrop M(6), Deleuze JF(5), Hannequin D(10), Genin E(11), Amouyel
P(12), Debette S(3), Lambert JC(13), Campion D(14); CNR MAJ collaborators.

Collaborators: Hannequin D, Campion D, Wallon D, Martinaud O, Zarea A, Nicolas G,
Rollin-Sillaire A, Bombois S, Mackowiak MA, Deramecourt V, Pasquier F, Michon A, 
Le Ber I, Dubois B, Godefroy O, Etcharry-Bouyx F, Chauviré V, Chamard L, Berger
E, Magnin E, Dartigues JF, Auriacombe S, Tison F, Sayette V, Castan D, Dionet E, 
Sellal F, Rouaud O, Thauvin C, Moreaud O, Sauvée M, Formaglio M, Mollion H,
Roullet-Solignac I, Vighetto A, Croisile B, Didic M, Félician O, Koric L,
Ceccaldi M, Gabelle A, Marelli C, Labauge P, Jonveaux T, Vercelletto M,
Boutoleau-Bretonnière C, Castelnovo G, Paquet C, Dumurgier J, Hugon J, De
Boisgueheneuc F, Belliard S, Bakchine S, Sarazin M, Barrellon MO, Laurent B,
Blanc F, Pariente J, Jurici S.

Author information: 
(1)Inserm, U1167, RID-AGE-Risk Factors and Molecular Determinants of
Aging-Related Diseases, Lille, France; Institut Pasteur de Lille, Lille, France; 
University Lille, U1167-Excellence Laboratory LabEx DISTALZ, Lille, France.
(2)Department of Genetics and CNR-MAJ, Normandie Univ, UNIROUEN, Inserm U1245 and
Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine,
Rouen, France.
(3)University of Bordeaux, Inserm, Bordeaux Population Health Research Center,
UMR1219, Bordeaux, France.
(4)Department of Neurology and CNR-MAJ, Normandie Univ, UNIROUEN, Inserm U1245
and Rouen University Hospital, Normandy Centre for Genomic and Personalized
Medicine, Rouen, France.
(5)Centre National de Génotypage, Institut de Génomique, CEA, Evry, France.
(6)McGill University and Génome Québec Innovation Centre, Montréal, Canada.
(7)CNR-MAJ, and Department of Neurology, Université de Lille, CHU, Inserm UMR-S
1171, Lille, France.
(8)Inserm UMR-1087/CNRS UMR 6291, l'institut du thorax, Univ. Nantes, Nantes,
France.
(9)Department of Genetics, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen
University Hospital, Normandy Centre for Genomic and Personalized Medicine,
Rouen, France.
(10)Department of Neurology and CNR-MAJ, Normandie Univ, UNIROUEN, Inserm U1245
and Rouen University Hospital, Normandy Centre for Genomic and Personalized
Medicine, Rouen, France; Department of Genetics, Neurology and CNR-MAJ, Normandie
Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Normandy Centre for
Genomic and Personalized Medicine, Rouen, France.
(11)Inserm UMR-1078, CHRU Brest, Univ. Brest, Brest, France.
(12)Inserm, U1167, RID-AGE-Risk Factors and Molecular Determinants of
Aging-Related Diseases, Lille, France; Institut Pasteur de Lille, Lille, France; 
University Lille, U1167-Excellence Laboratory LabEx DISTALZ, Lille, France;
Centre Hospitalier Universitaire de Lille, Epidemiology and Public Health
Department, Lille, France.
(13)Inserm, U1167, RID-AGE-Risk Factors and Molecular Determinants of
Aging-Related Diseases, Lille, France; Institut Pasteur de Lille, Lille, France; 
University Lille, U1167-Excellence Laboratory LabEx DISTALZ, Lille, France.
Electronic address: jean-charles.lambert@pasteur-lille.fr.
(14)Department of Genetics and CNR-MAJ, Normandie Univ, UNIROUEN, Inserm U1245
and Rouen University Hospital, Normandy Centre for Genomic and Personalized
Medicine, Rouen, France; Department of Research, Centre hospitalier du Rouvray,
Sotteville-lès-Rouen, France. Electronic address:
dominique.campion@univ-rouen.fr.

We performed whole-exome and whole-genome sequencing in 927 late-onset Alzheimer 
disease (LOAD) cases, 852 early-onset AD (EOAD) cases, and 1273 controls from
France. We assessed the evidence for gene-based association of rare variants with
AD in 6 genes for which an association with such variants was previously claimed.
When aggregating protein-truncating and missense-predicted damaging variants, we 
found exome-wide significant association between EOAD risk and rare variants in
SORL1, TREM2, and ABCA7. No exome-wide significant signal was obtained in the
LOAD sample, and significance of the order of 10-6 was observed in the whole AD
group for TREM2. Our study confirms previous gene-level results for TREM2, SORL1,
and ABCA7 and provides a clearer insight into the classes of rare variants
involved. Despite different effect sizes and varying cumulative minor allele
frequencies, the rare protein-truncating and missense-predicted damaging variants
in TREM2, SORL1, and ABCA7 contribute similarly to the heritability of EOAD and
explain between 1.1% and 1.5% of EOAD heritability each, compared with 9.12% for 
APOE ε4.

Copyright © 2017 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.neurobiolaging.2017.07.001 
PMID: 28789839  [Indexed for MEDLINE]

